Rocket Pharmaceuticals (RCKT) Highlights Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 'Process B' for Fanconi Anemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Rocket Pharmaceuticals (RCKT) Prices 3.82M Share Common Offering at $22.25/Sh
December 11, 2019 5:59 AM ESTRocket Pharmaceuticals, Inc. (NASDAQ:... More
Rocket Pharmaceuticals (RCKT) Announces Proposed Common Share Offering
December 10, 2019 4:02 PM ESTRocket... More
Rocket Pharmaceuticals (RCKT) PT Raised to $33 at Chardan Capital Markets
December 9, 2019 8:02 AM ESTChardan Capital Markets analyst Geulah Liveshits raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $33.00 (from $30.00) while maintaining a Buy rating.
The analyst commented, "On 8 November, Rocket Pharmaceuticals presented preliminary data on ex vivo lentiviral gene therapy RP-L102 for Fanconi anemia (FA), manufactured with commercial-grade "Process B", demonstrating (1) 2-3x higher product vector copy numbers (VCNs) vs. Process A product, and (2) signals of engraftment in patients at 6 months. The data, presented in a poster at the American Society of Hematology (ASH) 2019 Annual... More
Rocket Pharmaceuticals (RCKT) Reports Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I
December 9, 2019 7:02 AM ESTRocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces preliminary data from its Phase 1/2 clinical trial of RP-L201, the Companys lentiviral vector... More
Rocket Pharmaceuticals (RCKT) PT Raised to $41 at Baird, Added to Fresh Pick List
December 6, 2019 8:16 AM ESTBaird analyst Madhu Kumar raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $41.00 (from $30.00) while maintaining a Outperform rating.
Adds to Fresh Pick list.The analyst comments "Prior to Rocket Pharmaceuticals' (RCKT) data release at the American Society... More
